KUALA LUMPUR: Malaysian Genomics Resource Centre Bhd's (MGRC) subsidiary MGRC Healthcare Sdn Bhd has teamed up with De Cell Bhd to advance the Exogenetix programme, aiming to set new standards in cell-gene therapy development and commercialisation.
MGRC Healthcare will use its expertise in biopharmaceuticals to provide technical and production support, improving the efficiency and market presence of the Exogenetix programme.
De Cell Bhd will handle exclusive marketing responsibilities to enhance the programme's visibility and success.
MGRC said the collaboration underscores its commitment to innovation in healthcare and its dedication to pushing the boundaries of medical science.
"By combining production capabilities with marketing expertise, the partnership aims to significantly expand the impact of the Exogenetix program," it added.
MGRC executive chairman Azri Azerai said the partnership not only aligns with its strategic vision to deliver cutting-edge healthcare solutions but also reinforces its dedication to pushing the boundaries of medical science.
"Through this partnership, we are set to accelerate the development and delivery of next-generation cell-gene therapies, ultimately improving patient outcomes. We are eager to see the transformative impact this collaboration will have on the healthcare industry," said De Cell Bhd director Dr Lim Wooi Khai.
"This strategic alliance aims to support the ongoing evolution of the biopharmaceutical sector by integrating advanced biotechnologies with effective marketing strategies, thereby addressing the increasing needs for sophisticated therapeutic options,"